RXST Earnings

RXST reported its FY2025Q4 earnings on 2026-03-03, showcasing a revenue of 0.00 against an estimate of 33.00M, resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.41 by 0% . The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following RXST's FY2025Q4 earnings announcement on 2026-03-03, the stock price moved by % on the day of the release. Over the subsequent five days, it saw a % change. Historically, RXST's stock price tends to shift by an average of -0.54% in the 10 days leading up to earnings and +6.84% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate RXST’s annual revenue to reach 28.00M, while the EPS is projected at 0.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 2.86% and EPS estimates Revise Downward by -3.68% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between RXST's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Upward by 2.86%, while EPS estimates moved Revise Downward by -3.68% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, RXST's stock price typically moves by -0.54% in the 10 days before its earnings and +6.84% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 0.00 and revenue of 28.00M.

The earnings call highlighted several concerns: a larger GAAP net loss, increased operating expenses, and weak revenue guidance for 2025. Although gross margin is expected to improve, the company anticipates lower margins in the near term. The Q&A revealed uncertainties about competitive pressures and reimbursement changes, with management offering vague responses on key metrics. Despite some optimism around international expansion and premium IOL demand, the market's reaction is likely to be negative due to financial weaknesses and unclear guidance, especially given the company's small-cap status.